Cephalon pays $425 million to settle claims of off-label marketing

Share this article:
Cephalon pays $425 million to settle claims of off-label marketing
Cephalon pays $425 million to settle claims of off-label marketing

Cephalon said it will pay $425 million to settle a US Justice Department investigation into practices of off-label marketing of products including its pain reliever Actiq.

Actiq is approved by the FDA for use in cancer patients but is often prescribed by physicians off-label for other types of pain, such as migraine headaches.

Doctors are allowed to prescribe FDA-OK'd drugs for any condition, but drugmakers are only allowed to market them for uses approved by the agency. 

Cephalon has agreed to a single misdemeanor violation of the US Food, Drug and Cosmetic Act and will enter into a corporate-integrity agreement with the Department of Health and Human Services.
 
The settlement with the US Attorney's Office in Philadelphia and the US Department of Justice covers federal and state Medicaid claims.

Cephalon has denied that it marketed Actiq outside its indication, however the company's promotional practices have come under scrutiny of the US attorney in Philadelphia and Connecticut.

Cephalon has increased its existing financial reserves for the settlement and said the Connecticut investigation is still ongoing.

Meanwhile, the company reported a third-quarter loss of $306.7 million, compared to a profit of $95.7 million last year. Cephalon's sales in the quarter fell 9% to $438.4 million.
 

Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?